CARE-MS I, CARE-MS II, and CAMSS223 showed marked improvement in the EDSS score as 43% of patients showed confirmed disability improvement (CDI) when switched from IFN-b to alemtuzumab [10,11]. This evidence concerns the gene IFNB1 and myeloid sarcoma.